# Phase 2 Renal Insufficiency, Chronic trials: 34 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 34 trials in phase 2 for Renal Insufficiency, Chronic that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 2 Renal Insufficiency, Chronic trials: 34 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-2/renal-insufficiency-chronic

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 34
- Recruiting or not yet: 34
- Read on: November 19, 2026

## Trials

The 25 newest of 34, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 2, 2026 | NCT07911124 | Ticagrelor for Inflammation and Cardiovascular Risk in Patients With Chronic Kidney Disease | University of Arkansas | Phase 2 | Recruiting | Chronic Kidney Disease (CKD) | 230 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07911124) |
| August 25, 2026 | NCT07783802 | A Study of Clazakizumab (LY5724886) in Adults With Elevated hsCRP and at Increased Risk for Cardiovascular Event | Eli Lilly and Company | Phase 2 | Recruiting | Atherosclerosis, Cardiovascular Disease, Obesity, Hypertension, Diabetes Mellitus, Type 2, Renal Insufficiency, Chronic | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07783802) |
| July 24, 2026 | NCT07725497 | A Study of Luspatercept in People With Anemia | Memorial Sloan Kettering Cancer Center | Phase 2 | Recruiting | Anemia, Chronic Kidney Disease | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07725497) |
| July 20, 2026 | NCT07715318 | Efficacy and Safety of Spironolactone in Pediatric Hemodialysis Patients With Anemia. | Ain Shams University | Phase 2 | Not yet recruiting | Anemia | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07715318) |
| July 9, 2026 | NCT07693543 | Nicotinamide Riboside Supplementation in Chronic Kidney Disease | University of California, San Diego | Phase 2 | Not yet recruiting | Chronic Kidney Disease | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07693543) |
| June 17, 2026 | NCT07654231 | REducing Systemic Inflammation With LOw-dose Colchicine to ImproVE Cardiovascular Calcification in Chronic Kidney Disease: A Pilot... | University of Texas Southwestern Medical Center | Phase 2 | Not yet recruiting | Chronic Kidney Disease Mineral and Bone Disorder, Cognitive Function, Vascular Calcification, Coronary Artery... | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07654231) |
| June 15, 2026 | NCT07647133 | A Phase II Clinical Trial of Efficacy and Safety of SAL0140 at Different Doses in Patients With Chronic Kidney Disease | Shenzhen Salubris Pharmaceuticals Co., Ltd. | Phase 2 | Not yet recruiting | Chronic Kidney Disease | 249 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07647133) |
| June 12, 2026 | NCT07645300 | LOw DosE Spironolactone, chlorThAlidone oR Combination in CKD Trial | VA Office of Research and Development | Phase 2 | Not yet recruiting | Hypertension Treated With Antihypertensive Drugs, Chronic Kidney Disease, 3B and 4 | 160 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07645300) |
| April 28, 2026 | NCT07555054 | A Study of the Effect and Safety of HS-10390 in the Treatment of Participants With Chronic Kidney Disease | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Phase 2 | Not yet recruiting | Chronic Kidney Disease | 182 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07555054) |
| January 8, 2026 | NCT07325201 | Mitigating DKA in Type 1 Diabetes for Safe Use of SGLT Inhibitors Using Dual Continuous Ketone and Glucose Monitoring. | HealthPartners Institute | Phase 2 | Not yet recruiting | Type 1 Diabetes Mellitus, Chronic Kidney Disease (CKD) With Diabetes Mellitus (DM), Chronic Kidney Disease, Diabetic... | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07325201) |
| January 7, 2026 | NCT07323095 | Evaluate the Efficacy and Safety of ABP-671 in Subjects With Chronic Kidney Disease and Hyperuricaemia | Atom Therapeutics Co., Ltd | Phase 2 | Recruiting | Chronic Kidney Disease | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07323095) |
| December 9, 2025 | NCT07271186 | Study to Assess the Effects of ALN-ANG3 in Adult Participants With Diabetic Kidney Disease | Regeneron Pharmaceuticals | Phase 2 | Recruiting | Diabetic Kidney Disease (DKD) | 195 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07271186) |
| December 8, 2025 | NCT07268638 | A Study of Praliciguat in Participants With Focal Segmental Glomerulosclerosis (FSGS) | Akebia Therapeutics | Phase 2 | Recruiting | Focal Segmental Glomerulosclerosis | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07268638) |
| October 3, 2025 | NCT07206290 | Albuminuria Reduction Study With Survodutide Treatment in Kidney Disease | University Medical Center Groningen | Phase 2 | Not yet recruiting | Chronic Kidney Disease | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07206290) |
| September 26, 2025 | NCT07194590 | Equol and Vascular Function in Women With Chronic Kidney Disease | University of Colorado, Denver | Phase 2 | Recruiting | Chronic Kidney Disease (Stage 3-4), Vascular Function, Cognitive Functions, Cerebrovascular Function, Blood Pressure | 74 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07194590) |
| August 21, 2025 | NCT07134335 | UBT251 Injection Phase II Clinical Study (CKD) | The United Bio-Technology (Hengqin) Co., Ltd. | Phase 2 | Recruiting | Obesity &Amp; Overweight, Chronic Kidney Disease | 180 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07134335) |
| June 19, 2025 | NCT07029503 | Swedish Cardiac And Renal Failure Study-1 | Karolinska Institutet | Phase 2 | Recruiting | HFrEF - Heart Failure With Reduced Ejection Fraction, Chronic Kidney Disease | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07029503) |
| April 16, 2025 | NCT06929169 | Cardiovascular Effects of SGLT2 Inhibitors in Hemodialysis Patients: A Phase 2 Randomized Study | Sponsor not shown (see the record) | Phase 2 | Recruiting | Chronic Kidney Disease Requiring Hemodialysis | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06929169) |
| April 11, 2025 | NCT06923709 | Beneficial Effect of Amiloride on Progression of Chronic Kidney Disease | Odense University Hospital | Phase 2 | Recruiting | Chronic Kidney Disease(CKD), Proteinuria | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06923709) |
| April 6, 2025 | NCT06913647 | Effect of Canagliflozin on Ultrafiltration & Fibrosis in Patients on Peritoneal Dialysis | McGill University Health Centre/Research Institute of the McGill University Health Centre | Phase 2 | Recruiting | ESRD, CKD (Chronic Kidney Disease) Stage 5D | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06913647) |
| March 27, 2025 | NCT06897605 | Impact of Dapagliflozin in Anemic Chronic Kidney Disease Patients | Mansoura University | Phase 2 | Recruiting | Chronic Kidney Disease(CKD), Anemia, Kidney Disease, Chronic | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06897605) |
| February 25, 2025 | NCT06843902 | Improving Coronary Vascular Health in Women | Massachusetts General Hospital | Phase 2 | Recruiting | HIV-1-infection, Coronary Microvascular Dysfunction, Metabolic Disease | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06843902) |
| January 27, 2025 | NCT06794593 | Effect Camostat for Kidney Protection in Chronic Kidney Disease | Odense University Hospital | Phase 2 | Recruiting | Chronic Kidney Disease(CKD) | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06794593) |
| December 5, 2024 | NCT06717698 | A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic... | Novo Nordisk A/S | Phase 2 | Recruiting | Chronic Kidney Disease | 465 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06717698) |
| September 19, 2024 | NCT06593392 | Safety and Tolerability of Difelikefalin in Adolescents on Haemodialysis With Moderate-to-Severe Pruritus | Vifor Fresenius Medical Care Renal Pharma | Phase 2 | Recruiting | Pruritus, Chronic Kidney Diseases | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06593392) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| Emory University | 2 |
| Odense University Hospital | 2 |
| University of Colorado, Denver | 2 |
| McGill University Health Centre/Research Institute of the McGill University Health Centre | 2 |
| Karolinska Institutet | 1 |
| [Regeneron Pharmaceuticals](https://specstream.ai/data/clinical-trials/company/regeneron-pharmaceuticals) | 1 |
| St. Louis University | 1 |
| Ain Shams University | 1 |
| Memorial Sloan Kettering Cancer Center | 1 |
| Massachusetts General Hospital | 1 |
| Vifor Fresenius Medical Care Renal Pharma | 1 |
| The University of Hong Kong | 1 |
| The United Bio-Technology (Hengqin) Co., Ltd. | 1 |
| HealthPartners Institute | 1 |
| [Eli Lilly and Company](https://specstream.ai/data/clinical-trials/company/eli-lilly-and-company) | 1 |
| University of California, San Diego | 1 |
| University of Arkansas | 1 |
| Mansoura University | 1 |
| VA Office of Research and Development | 1 |
| University of Texas Southwestern Medical Center | 1 |
| Atom Therapeutics Co., Ltd | 1 |
| [Jiangsu Hansoh Pharmaceutical Co., Ltd.](https://specstream.ai/data/clinical-trials/company/jiangsu-hansoh-pharmaceutical-co-ltd) | 1 |
| University of California, Davis | 1 |
| [Novo Nordisk A/S](https://specstream.ai/data/clinical-trials/company/novo-nordisk-a-s) | 1 |
| [Akebia Therapeutics](https://specstream.ai/data/clinical-trials/company/akebia-therapeutics) | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 18 |
| China | 5 |
| Denmark | 3 |
| Argentina | 3 |
| Spain | 2 |
| Japan | 2 |
| Canada | 2 |
| Australia | 2 |
| Sweden | 1 |
| Greece | 1 |
| Israel | 1 |
| Saudi Arabia | 1 |
| United Arab Emirates | 1 |
| United Kingdom | 1 |
| Hong Kong | 1 |
| Puerto Rico | 1 |
| Egypt | 1 |
| Brazil | 1 |
| Bulgaria | 1 |
| Czechia | 1 |
| India | 1 |
| Italy | 1 |
| Malaysia | 1 |
| Poland | 1 |
| South Korea | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Pharmaceutical products wholesalers in the United States](https://specstream.ai/data/businesses/pharmaceutical-products-wholesalers/united-states)
- [Sake bars in the United States](https://specstream.ai/data/businesses/sake-bars/united-states)
- [Test preparation centers in the United States](https://specstream.ai/data/businesses/test-preparation-centers/united-states)
- [Window washing companies in the United States](https://specstream.ai/data/businesses/window-washing-companies/united-states)
- [B2B newspaper advertising companies in the United States](https://specstream.ai/data/businesses/b2b-newspaper-advertising-companies/united-states)
- [Cancer treatment centers in the United States](https://specstream.ai/data/businesses/cancer-treatment-centers/united-states)
